Statins, Dementia & Side Effects: Separating Evidence From Influencer Myths (Portland • Lake Oswego • USA)

One-Minute Read

The brain is one of the most cholesterol-rich organs in the body, but that does not mean high circulating LDL is necessary for normal brain function. The blood-brain barrier prevents most cholesterol carried in LDL and other circulating lipoproteins from freely entering the central nervous system. The brain therefore produces, recycles and regulates most of its cholesterol locally.

Lowering LDL in the bloodstream is not the same thing as depriving neurons of cholesterol.

Large randomized trials and modern systematic reviews have not found that statins cause progressive cognitive decline or dementia. Even among patients whose LDL has been lowered to extremely low levels with intensive lipid-lowering therapy, formal cognitive testing has not shown deterioration attributable to the lower LDL level.

Rare reports of memory loss, forgetfulness or confusion have occurred with statins. Those symptoms deserve attention when they occur, but they have generally been reported as nonserious and reversible. They are not evidence that statins cause Alzheimer’s disease.

At the same time, vascular disease is itself an important contributor to cognitive decline. High LDL in midlife is now recognized as a potentially modifiable dementia risk factor, and stroke, small-vessel disease, hypertension, diabetes and atherosclerosis all matter to long-term brain health.

The brain needs cholesterol. It does not need untreated atherosclerosis.

Yes, the Brain Needs Cholesterol

There is no dispute about the importance of cholesterol to the nervous system. Cholesterol is a structural component of neuronal membranes and myelin, and it plays an important role in synapse formation, receptor function and communication between neurons.

What is often missed is that cholesterol metabolism inside the brain is very different from cholesterol metabolism in the bloodstream.

The blood-brain barrier largely prevents cholesterol carried in circulating LDL and VLDL particles from entering the central nervous system. The adult brain therefore synthesizes and recycles cholesterol locally.

Astrocytes are an important source of newly synthesized cholesterol in the brain. That cholesterol can be transported to neurons on locally produced lipoprotein particles containing apolipoprotein E, better known as ApoE.

This is one reason discussions about cholesterol and Alzheimer’s disease can become confusing. ApoE plays a major role in lipid transport within the brain, but ApoE-containing particles in the central nervous system are not the same as the LDL particles measured on a standard blood lipid panel.

Blood LDL and brain cholesterol are part of the same broad lipid biology, but they are not interchangeable pools.

Lowering Blood LDL Does Not Deplete Brain Cholesterol

Statins inhibit HMG-CoA reductase, an enzyme involved in cholesterol synthesis. One of the major clinical effects is increased LDL-receptor activity in the liver, allowing the liver to remove more LDL particles from the circulation.

The result is lower circulating LDL and less exposure of the arterial wall to atherogenic particles.

An LDL level of 60 mg/dL, 40 mg/dL or even 20 mg/dL does not represent the amount of cholesterol available to neurons. Blood LDL concentration and brain cholesterol availability are not the same measurement.

This question has become especially relevant because modern lipid-lowering therapy can now produce LDL levels far below what was routinely achieved in earlier decades. If very low circulating LDL deprived the brain of cholesterol, we would expect cognitive problems to become increasingly apparent as LDL falls.

That pattern has not emerged.

What Happens When LDL Gets Very Low?

The EBBINGHAUS cognitive study and its long-term follow-up provide some of the most useful evidence on this question.

Participants with established cardiovascular disease received intensive LDL lowering that included statin therapy and the PCSK9 inhibitor evolocumab.

In the long-term follow-up published in NEJM Evidence, median LDL cholesterol was approximately 35 mg/dL. Participants were followed for a median additional 5.1 years, with some followed for more than seven years from their original randomization.

Researchers found no deterioration in executive function associated with prolonged exposure to these very low LDL levels.

Earlier FOURIER cognitive data involving more than 22,000 participants reached a similar conclusion. People whose LDL fell below 20 mg/dL did not report greater cognitive decline than participants with substantially higher LDL levels.

No study can answer every possible question about cholesterol and cognition, but these findings provide strong reassurance against the claim that lowering circulating LDL routinely “starves” the brain of cholesterol.

What Do Randomized Trials Show About Statins and Cognition?

The strongest clinical evidence does not show that statins cause progressive cognitive deterioration.

A 2025 systematic review and meta-analysis of randomized clinical trials included 20 trials, with more than 139,000 participants represented in studies reporting dementia or cognitive impairment outcomes. Lipid-lowering treatment was not associated with an increased incidence of dementia or cognitive impairment.

Another large systematic review examined 42 randomized studies involving more than 150,000 participants. Cholesterol-lowering medications were not associated with an increase in neurocognitive events. The same pattern was seen when statins, ezetimibe and PCSK9 inhibitors were examined individually.

The American Heart Association reached the same general conclusion in its scientific review of aggressive LDL lowering and brain health. The overall body of randomized and observational evidence does not support the claim that statins or intensive LDL lowering cause dementia or persistent cognitive impairment.

What About Reports of Memory Problems With Statins?

Memory complaints associated with statin use have been reported, and they should not be dismissed when a patient experiences them.

Postmarketing reports have included memory loss, forgetfulness, confusion and related cognitive symptoms. FDA-approved atorvastatin labeling notes that these reports have generally been nonserious and reversible after discontinuation, with a median reported resolution time of approximately three weeks.

Postmarketing reports cannot tell us how frequently a symptom occurs or prove that the medication caused every reported event. Still, a clear change in cognition after starting a statin or increasing the dose warrants clinical attention.

The evaluation should include the timing of symptoms, the statin and dose being used, other medications and other common contributors to cognitive complaints, including:

• poor sleep or sleep apnea
• thyroid dysfunction
• blood pressure abnormalities
• glucose dysregulation and insulin resistance
• alcohol use
• depression or anxiety
• other medications
• neurological or metabolic conditions

A temporary medication-associated symptom can be clinically important. It is not the same thing as evidence that statins cause Alzheimer’s disease or progressive neurodegeneration.

Memory Complaints Are Not the Same as Dementia

Forgetfulness, word-finding difficulty, mental fatigue and “brain fog” are common symptoms with many possible causes. Sleep deprivation, menopause, depression, thyroid disease, medications, alcohol, insulin resistance and sleep apnea can all affect cognition.

Progressive neurodegenerative dementia is a different clinical problem.

This matters when personal anecdotes are used as evidence. Someone may notice that a friend or family member has been taking a statin for years and later develops cognitive impairment. That observation alone cannot establish causation.

People who take statins are often older and may also have hypertension, diabetes, insulin resistance, coronary disease, carotid disease, obesity, smoking exposure or other vascular risk factors. Those conditions independently increase the risk of cognitive decline.

In other words, the same cardiovascular disease that led to the statin prescription may also contribute to later cognitive impairment. That is precisely why randomized trials and carefully designed observational studies are more informative than individual anecdotes.

Vascular Disease Matters to the Brain

The brain depends on healthy blood vessels. Cognitive aging is influenced by far more than amyloid and tau.

Stroke, cerebral small-vessel disease, hypertension, diabetes, atrial fibrillation, endothelial dysfunction and atherosclerosis can all affect brain function. The American Heart Association's 2026 clinical update on vascular contributions to cognitive impairment reinforces how closely vascular health and cognitive health are connected.

Atherosclerosis can involve the coronary arteries, carotid arteries and cerebral circulation. It can cause a major ischemic stroke, but vascular injury does not have to produce a dramatic stroke to matter. Small-vessel disease and cumulative vascular injury can also contribute to cognitive decline over time.

Vascular health is part of brain health.

For more on this connection, see ApoB and Brain Health: Why Vascular Risk Matters for Cognitive Longevity.

What About High LDL and Dementia?

The relationship between cholesterol and dementia is more complicated than either side of the internet debate often suggests.

The 2024 Lancet Commission on dementia prevention added high LDL cholesterol in midlife to its list of potentially modifiable dementia risk factors.

That does not mean LDL is the sole cause of Alzheimer’s disease. Dementia risk is influenced by age, genetics, ApoE genotype, metabolic health, blood pressure, vascular disease, smoking, physical activity, hearing, sleep and many other factors.

It does mean that prolonged exposure to elevated atherogenic particles should not be assumed to protect the brain simply because the brain contains cholesterol.

This is also why HormoneSynergy® looks beyond a standard LDL-C value. LDL-C and ApoB measure different aspects of atherogenic risk. ApoB provides information about the number of circulating atherogenic particles capable of entering the arterial wall, which can be particularly useful when LDL-C alone does not tell the full story.

JUPITER: Why Stroke Belongs in This Discussion

The JUPITER trial was not a dementia trial, but it remains relevant because stroke is brain injury.

JUPITER randomized 17,802 apparently healthy men and women whose LDL cholesterol was below 130 mg/dL but whose high-sensitivity C-reactive protein, or hsCRP, was at least 2 mg/L. Participants received rosuvastatin 20 mg daily or placebo.

Rosuvastatin lowered LDL by approximately 50% and produced substantial reductions in major cardiovascular events. The independent monitoring board recommended stopping the trial early after a prespecified efficacy boundary had been crossed, with a median follow-up of 1.9 years.

Compared with placebo, rosuvastatin was associated with approximately:

• 44% lower risk of the primary composite cardiovascular endpoint
• 54% lower risk of myocardial infarction
• 48% lower risk of stroke
• 51% lower risk of ischemic stroke in the dedicated stroke analysis

There was no significant increase in hemorrhagic stroke in that analysis.

JUPITER does not prove that statins prevent dementia. It does show why a serious discussion of cholesterol and brain health cannot ignore vascular outcomes. Preventing an ischemic stroke is one very direct way of protecting the brain.

Do Statins Prevent Alzheimer's Disease?

Several observational studies have associated statin use with a lower incidence of dementia or Alzheimer’s disease, and some recent meta-analyses have reported similar associations.

That evidence is interesting, but observational associations are not the same as randomized proof that statins prevent Alzheimer’s disease.

The randomized evidence is much stronger on a different point: statins do not appear to cause dementia.

Whether statins themselves reduce Alzheimer’s disease risk beyond their established effects on atherosclerotic cardiovascular disease and ischemic stroke remains less certain.

What About Lipophilic and Hydrophilic Statins?

Another common claim is that lipophilic statins such as simvastatin and atorvastatin are dangerous to the brain because they cross the blood-brain barrier more readily, while hydrophilic statins such as rosuvastatin and pravastatin are considered “brain safe.”

There are real pharmacological differences among statins, and those differences can matter when choosing a medication for an individual patient. Current outcome data, however, do not establish that commonly used lipophilic statins cause dementia while hydrophilic statins do not.

If a patient develops reproducible symptoms with one statin, changing the dose or switching to another agent may be entirely reasonable. That is individualized medication management. It is not evidence that statins as a class cause neurodegenerative disease.

Where Statins Fit at HormoneSynergy®

Statins are among the most extensively studied medications in cardiovascular medicine, and we have no problem prescribing them when they are clinically indicated.

The decision should be based on the patient's actual cardiovascular risk rather than fear of cholesterol or fear of medication.

Depending on the individual, that assessment may include:

• LDL cholesterol
• ApoB and LDL particle burden
• Lipoprotein(a)
• triglycerides and metabolic health
• fasting insulin and glucose regulation
• blood pressure
• inflammatory markers such as hsCRP
• smoking history
• kidney function
• family and personal cardiovascular history
• coronary artery calcium
• carotid imaging
• CCTA or Cleerly® analysis when appropriate
• existing coronary, carotid or peripheral atherosclerosis

Lifestyle remains foundational, including nutrition, exercise, resistance training, sleep, weight management, smoking cessation and good metabolic control. But lifestyle and medication are not competing philosophies. When medication meaningfully reduces risk, it should be used.

For patients with substantial plaque burden, markedly elevated ApoB, familial hypercholesterolemia or established cardiovascular disease, aggressive LDL lowering may be one of the most important interventions available.

Learn more about the HormoneSynergy® Preventive Cardiology approach.

The Better Question

Asking whether the brain needs cholesterol is not particularly useful. Of course it does.

The clinically important questions are where brain cholesterol comes from, whether circulating LDL supplies it, whether lowering LDL impairs cognition, what happens when LDL becomes very low and how vascular disease affects the aging brain.

The evidence gives us a fairly clear picture. The brain synthesizes and regulates most of its cholesterol behind the blood-brain barrier. Large randomized datasets do not show progressive cognitive impairment from statins or from very low circulating LDL. High LDL exposure in midlife is now recognized as a potentially modifiable dementia risk factor, while vascular disease remains an important and preventable contributor to cognitive decline.

The brain needs cholesterol. That is not an argument for keeping LDL or ApoB unnecessarily high.

Medicine, Not Marketing

Statins should not be prescribed simply because someone is frightened by a cholesterol number. They also should not be avoided because someone on social media says the brain is “made of cholesterol.”

Neither approach reflects good medicine.

The better approach is to define the patient's actual risk. Look at ApoB, Lp(a), metabolic health, blood pressure, family history, smoking exposure and, when appropriate, the presence and extent of atherosclerotic plaque. Then treat that risk appropriately.

Protecting the arteries and protecting the brain are not competing goals. In preventive longevity medicine, they are often part of the same strategy.

Frequently Asked Questions

Does lowering LDL deprive the brain of cholesterol?

No. The brain produces and regulates most of its cholesterol locally because circulating LDL particles do not freely cross the blood-brain barrier. Blood LDL and brain cholesterol are largely separate cholesterol pools.

Do statins cause dementia?

Current randomized trial evidence and large systematic reviews do not show that statins cause dementia or progressive cognitive decline.

Can statins cause memory problems?

Rare postmarketing reports of memory loss, forgetfulness and confusion have occurred. FDA-approved labeling notes that reported cognitive symptoms have generally been nonserious and reversible after statin discontinuation. These reports are different from progressive dementia.

Can LDL become too low for the brain?

Clinical trials have studied people with LDL levels below 20 mg/dL and long-term cohorts with median LDL around 35 mg/dL without finding associated deterioration in cognitive function. That does not mean every patient needs an LDL that low. It does provide strong reassurance that very low circulating LDL does not appear to deprive the brain of cholesterol.

Does high LDL increase dementia risk?

High LDL cholesterol in midlife was added to the 2024 Lancet Commission's list of potentially modifiable dementia risk factors. Dementia is multifactorial, so LDL should be considered alongside blood pressure, diabetes, exercise, smoking, hearing, sleep, vascular disease and other contributors.

Do statins prevent Alzheimer's disease?

Observational studies have sometimes associated statin use with lower dementia or Alzheimer's risk, but randomized clinical trials have not established statins as an Alzheimer's prevention treatment. Their established benefits include reducing atherosclerotic cardiovascular events and ischemic stroke in appropriately selected patients.

Why is the JUPITER trial relevant to brain health?

JUPITER was a cardiovascular prevention trial, not a dementia trial. Rosuvastatin reduced stroke by approximately 48% and ischemic stroke by approximately 51%. Preventing ischemic stroke is an important component of protecting long-term brain health.

What should I do if I notice cognitive symptoms after starting a statin?

Discuss the symptoms with your clinician rather than stopping cardiovascular therapy without a plan. The timing of symptoms, statin and dose, other medications, sleep, thyroid function, metabolic health and other potential contributors should be reviewed. When appropriate, changing the dose or medication may be reasonable.

Related HormoneSynergy® Resources

• ApoB and Brain Health: Why Vascular Risk Matters for Cognitive Longevity
• LDL vs ApoB: What's the Difference and Why It Matters
• HormoneSynergy® Preventive Cardiology Protocol
• Statin Phobia: Who's Pushing It and Why It Can Be Dangerous

Selected References

• American Heart Association. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke.
• Zimerman A, et al. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab. NEJM Evidence. 2025.
• Reddin C, et al. Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis. Age and Ageing. 2025.
• The effects of cholesterol-lowering drugs on neurocognitive function: systematic review and meta-analysis.
• Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024.
• Everett BM, et al. Rosuvastatin in the prevention of stroke: JUPITER. Circulation.
• American Heart Association. Vascular Contributions to Cognitive Impairment and Brain Health. 2026.
• Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development. Brain. 2024.
• U.S. Food and Drug Administration. Atorvastatin prescribing information.